CNBC

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...
Reuters

Lilly, Novo Nordisk back direct-to-employer programs to expand access to weight-loss drugs

Nov 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access to its blockbuster weight-loss ...
CNBC

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...
Business Insider

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Better injections and better pills. It's official: Eli Lilly appears to be beating Novo Nordisk at the ...
FiercePharma

Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo

The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s orforglipron cruised past an FDA green light Wednesday. Now christened Foundayo, the ...